


---

# GLIOBLASTOMA MULTIFORME:

CD38 expression implications on  
glioblastoma progression and  
survival

Angela Bai, Hunter Nelson, Peyton Hall

---



---

# TABLE OF CONTENTS

01

## Glioblastoma Epidemiology

Epidemiology,  
pathophysiology, and  
treatment

02

## CD38 Background

CD38 as an immune  
glycoprotein overview

03

## Methods

TCGA-GGM data, RStudio and  
PANTHER methods

04

## Results

Glioblastoma patient volcano  
plot, CD38 survival KM plot,  
predictive model

05



## Discussion

---

---

01

# GLIOBLASTOMA BACKGROUND



# 304 days


Average survival time of GBM patients after diagnosis

# 12,000


Cases annually diagnosed within the US alone

# 15% of all primary brain tumors


The most complex, deadly, and treatment-resistant brain cancer




# NEURON and GLIAL CELLS





## Low-Grade Glioma




## Glioblastoma



# *Characteristics of glioblastoma multiforme and the possible therapeutic options*







Macrophage



Dendritic cell



Myeloid-derived suppressor cell



Neutrophil



B lymphocyte



T lymphocyte




Natural killer cell




Glioblastoma cell

(a)



# CD38

CD38 or cyclic ADP ribose hydrolase is a robust transmembrane glycoprotein involved in a variety of cellular functions including cell adhesion, differentiation, proliferation, signal transduction in immune responses, and calcium signaling through the synthesis of cyclic-ADP ribose (cADPR).





# Hypothesis

High CD38 expression and mutation may exacerbate glioblastoma tumorigenesis and reduce the overall survival time of patients that develop glioblastoma.

---

# 02

## METHODS

Analyzing expression rates and survival time in R

---

---

# R Methods

## High/Low CD38 Expression

1

- Literature review found cutoff to be at 25% expression
- Segmented patients into 2 categories: high vs low CD38

## Kaplan Meier Survival

2

- Compared survival over time

## Differential Expression Analysis

3

- Identified upregulated and downregulated genes

## PANTHER

4

- Biological pathways

## Lollipop Plot

5

- Mutations on CD38
-




---

03

**RESULTS**

---



Strata


— `cd38_expression=High`

— `cd38_expression=Low`


N = 86

# Volcano plot

*Enhanced Volcano*








## PANTHER Molecular Function- Upregulated Genes

N = 1290

Categorized = 328

- ATP-dependent activity (GO:0140657)
- binding (GO:0005488)
- catalytic activity (GO:0003824)
- molecular adaptor activity (GO:0060090)
- molecular function regulator activity (GO:0098772)
- molecular transducer activity (GO:0060089)
- structural molecule activity (GO:0005198)
- transcription regulator activity (GO:0140110)
- translation regulator activity (GO:0045182)
- transporter activity (GO:0005215)




## PANTHER Molecular Function-Downregulated Genes

N = 2436

Categorized = 195

- [ATP-dependent activity \(GO:0140657\)](#)
- [antioxidant activity \(GO:0016209\)](#)
- [binding \(GO:0005488\)](#)
- [catalytic activity \(GO:0003824\)](#)
- [cytoskeletal motor activity \(GO:0003774\)](#)
- [molecular function regulator activity \(GO:0098772\)](#)
- [molecular transducer activity \(GO:0060089\)](#)
- [structural molecule activity \(GO:0005198\)](#)
- [transcription regulator activity \(GO:0140110\)](#)
- [transporter activity \(GO:0005215\)](#)

CD38 : [Somatic Mutation Rate: 0.81%]  
NM\_001775



• Missense\_Mutation

---

# 04

## DISCUSSION

Significance of our findings

---



---

# Compared to literature

## Hypothesis Not Supported

We found that high CD38 expression is correlated with higher survival rates.

- Other genes impact CD38 expression
- Small sample size

## Medical Implications

Could CD38 reduce efficiency of biological processes?

## Gene Ratio

Total Upregulated Genes = 2436

Total Downregulated Genes = 1490

Upregulated and downregulated genes perform similar functions. By ratio, we identified twice as many upregulated genes than downregulated genes in RNA data.

However, this is not reflected in the PANTHER bar graph.


---

---

# Future Directions (pathways)

## Treatments

Current treatments are limited by blood brain barrier.



## Comparison Between Cancers

Examine why high CD38 expression is correlated with lower survival rates in glioblastoma, but improves prognosis in hepatocellular carcinoma (HCC) and breast cancer.

1. Run differential analysis expression on high/low CD38 cohorts in HCC and breast cancer
  2. Input upregulated and downregulated genes of both cancers into PANTHER
  3. Compare pathways with glioblastoma
-



---

# REFERENCES

- Byrd, J. C., & Flynn, J. M. (2014). 102 - Chronic Lymphocytic Leukemia, *Abeloff's Clinical Oncology* (Fifth Edition), Pages 1958-1978.e7. <https://doi.org/10.1016/B978-1-4557-2865-7.00102-8>.
- Grech, N., Dalli, T., Mizzi, S., Meilak, L., Calleja, N., & Zrinzo, A. (2020). Rising Incidence of Glioblastoma Multiforme in a Well-Defined Population. *Cureus*, 12(5), e8195. <https://doi.org/10.7759/cureus.8195>
- Levy, A., Blacher, E., Vaknine, H., Lund, F. E., Stein, R., & Mayo, L. (2012). CD38 deficiency in the tumor microenvironment attenuates glioma progression and modulates features of tumor-associated microglia/macrophages. *Neuro Oncol*, 14(8), 1037-1049. <https://doi.org/10.1093/neuonc/nos121>
- Nelson, J. S., Burchfiel, C. M., Fekedulegn, D., & Andrew, M. E. (2012). Potential risk factors for incident glioblastoma multiforme: the Honolulu Heart Program and Honolulu-Asia Aging Study. *J Neurooncol*, 109(2), 315-321. <https://doi.org/10.1007/s11060-012-0895-3>
- Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., Alexe, G., Lawrence, M., O'Kelly, M., Tamayo, P., Weir, B. A., Gabriel, S., Winckler, W., Gupta, S., Jakkula, L., . . . Cancer Genome Atlas Research, N. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. *Cancer Cell*, 17(1), 98-110. <https://doi.org/10.1016/j.ccr.2009.12.020>
- Wei, D. C., & Morrison, E. H. (2023). Histology, Astrocytes. In *StatPearls*. <https://www.ncbi.nlm.nih.gov/pubmed/31424726>
- Wrensch, M., Minn, Y., Chew, T., Bondy, M., & Berger, M. S. (2002). Epidemiology of primary brain tumors: current concepts and review of the literature. *Neuro Oncol*, 4(4), 278-299. <https://doi.org/10.1093/neuonc/4.4.278>
-

---

# Questions?

Thank you for your time and attention!

